ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer

Jul 20, 2009 - ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. FDA has approved revisions to the U.S. prescribing information for ERBITUX® (cetuximab) concerning the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).

The details can be read here.